Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC raised its position in Conduit Pharmaceuticals Inc. (NASDAQ:CDT) by 36.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 584,984 shares of the company’s stock after purchasing an additional 157,307 shares during the quarter. Geode Capital Management LLC owned about 56.79% of Conduit Pharmaceuticals worth $40,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Rhumbline Advisers boosted its stake in Conduit Pharmaceuticals by 5,034.0% during the 4th quarter. Rhumbline Advisers now owns 1,028,702 shares of the company’s stock valued at $71,000 after purchasing an additional 1,008,665 shares in the last quarter. 3.29% of the stock is currently owned by institutional investors and hedge funds.

Conduit Pharmaceuticals Stock Performance

CDT opened at $0.50 on Tuesday. The stock’s fifty day moving average is $0.81 and its 200-day moving average is $4.88. Conduit Pharmaceuticals Inc. has a one year low of $0.48 and a one year high of $350.00. The company has a market capitalization of $5.70 million, a PE ratio of -0.01 and a beta of 2.39.

Conduit Pharmaceuticals (NASDAQ:CDT) last released its earnings results on Friday, March 28th. The company reported ($20.33) EPS for the quarter.

Conduit Pharmaceuticals Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.